Axogen Inc Stock Price, News & Analysis

Axogen (AXGN) has announced organizational updates aimed at enhancing market development and innovation following strong preliminary second-quarter revenue of approximately $34.4 million, a 2% increase year-over-year. Changes include the sales team reporting directly to CEO Karen Zaderej and plans to appoint a new chief marketing officer. The company reaffirms its full-year revenue guidance of $135 million to $142 million with a gross margin above 80%. Further financial details will be released on August 3, 2022.

William Burke has joined the Axogen Board of Directors as chair of the Audit Committee, effective July 11, 2022. With over 25 years of experience in the medical technology sector, Burke has held senior roles at companies like Haemonetics, Medtronic, and Covidien. His extensive background in finance and business development is expected to strengthen Axogen’s leadership. Burke expressed excitement about contributing to Axogen's mission to improve patient outcomes in peripheral nerve repair, aligning with the company's innovative surgical solutions.

Axogen, a leader in surgical solutions for peripheral nerve injuries, announced presentations by CEO Karen Zaderej and CFO Peter J. Mariani at upcoming investor conferences. Mariani will speak at the Jefferies Virtual Healthcare Conference on June 9, 2022, at 10:30 a.m. ET, while Zaderej will present at the JMP Securities Life Sciences Conference on June 15, 2022, at 9:30 a.m. ET. The presentations will be available via live webcast on Axogen's Investor page, with replays archived for 90 days.

Axogen, Inc. (NASDAQ: AXGN) reported first-quarter 2022 financial results with net revenue of $31.0 million, unchanged from the same period in 2021. Adjusted net loss widened to $8.5 million or $0.20 per share, compared to $3.1 million or $0.08 per share last year. Gross margin decreased to 82.1% from 83.3%. The company expects 2022 revenue between $135.0 million and $142.0 million, reflecting anticipated growth. Key developments include the successful completion of the RECON Phase 3 study for Avance Nerve Graft, providing significant clinical evidence for its use.

Axogen announced that its RECON Clinical Study successfully met its primary endpoint by demonstrating the superiority of Avance Nerve Graft in returning sensory function in digital nerve injuries. The study showed that Avance outperformed conduits, especially in gaps exceeding 12 mm, achieving significant recovery times up to 3 months faster. With results supporting a Biologics License Application (BLA) submission in late 2023, this milestone bolsters Avance's market adoption potential.

Axogen, Inc. (NASDAQ: AXGN) announced it will release its first quarter 2022 financial results on May 4, 2022, after market close. The management team will conduct a conference call and webcast at 4:30 p.m. ET to discuss the results. Interested parties can join by calling (877) 407-0993 for the toll-free option or (201) 689-8795 directly. A live webcast will also be available on the company's website. Axogen is focused on innovative surgical solutions for peripheral nerve injuries, offering a range of products aimed at restoring nerve function.

Axogen, Inc. (NASDAQ: AXGN) reported Q4 and full-year 2021 financial results, showing a 3% decline in Q4 revenue at $31.5 million compared to Q4 2020. Full-year revenue rose 13% to $127.4 million.

The adjusted net loss for Q4 stood at $3.3 million, unchanged from the previous year, while the gross margin was 82.8%. The company anticipates 2022 revenue between $135 million and $142 million, projecting growth of 10% to 15% over 2021.

Axogen, Inc. (NASDAQ: AXGN) will participate in two upcoming investor conferences in February 2022. CEO Karen Zaderej will engage in a fireside chat at the BTIG Virtual MedTech Conference on February 15 at 1:25 p.m. ET and at the 11th Annual SVB Leerink Global Healthcare Conference on February 17 at 1:40 p.m. ET. Both discussions will be accessible via Axogen's Investors page, with a replay available post-event for 90 days. Axogen specializes in innovative solutions for peripheral nerve injuries, focusing on restoring nerve function and improving patient quality of life.